BioCopy Publishes ValidaTe® AI Discovery Platform on bioRxiv

Basel, 14 August 2026 — BioCopy AG, a portfolio company of Haute Capital Partners, has published the first public description of its ValidaTe® discovery platform as a preprint on bioRxiv. The publication marks the first time the platform, built over the past two years, has been described in full to the scientific community.

What ValidaTe® does
ValidaTe® combines artificial intelligence with high-throughput experimental validation to address off-target toxicity in TCR-mimic (TCRm) therapeutics, one of the central obstacles in the field. Off-target binding is what causes a cancer therapeutic to attack healthy tissue alongside tumour cells.

Applied to BioCopy’s lead MAGE-A4 programme, ValidaTe® produced an approximately 90% reduction in experimentally confirmed off-target binding compared with a benchmark molecule.

A closed-loop discovery workflow
The preprint describes the complete closed-loop workflow for the first time: proteome-wide AI prediction, high-throughput experimental validation, structural characterisation and functional confirmation. ValidaTe® now serves as the discovery engine for BioCopy’s TCRm pipeline.

The manuscript also introduces the proprietary WiFi™ (Widened Fingerprint) design principle, which combines complementary TCRm antibodies to broaden target recognition while maintaining selectivity.

Independent scientific validation
The work is co-authored with researchers from Charité Berlin and the Max Planck Institute of Biophysics in Frankfurt, giving investors, collaborators and the scientific community a transparent and citable description of the platform.

Read the preprint on bioRxiv: https://doi.org/10.64898/2026.07.30.741432

Haute Capital Partners’ position
Haute Capital Partners SA is a shareholder of BioCopy AG and participated in the company’s Series A financing as a key investor. Our investment in BioCopy reflects a wider focus on Swiss companies applying artificial intelligence to hard scientific problems.

About BioCopy AG
BioCopy AG is a Swiss-German biopharmaceutical company headquartered in Basel, with an R&D facility in Emmendingen (Germany). The company combines proprietary ultra-high-throughput screening technologies, artificial intelligence and wet-lab experimental feedback to develop next-generation biotherapeutics in immuno-oncology.

About Haute Capital Partners AG
Haute Capital Partners (BX Swiss: HAUTE) is Switzerland's listed private equity holding. Access high-growth Swiss companies through a single tradeable share, denominated in CHF. The company's registered shares are listed on the BX Swiss: Ticker: HAUTE | ISIN: CH1115678950 | Valor: 111567895 | www.haute.com

Investor Inquiries
Haute Capital Partners AG
+41 32 321 35 35 | ir@haute.com

Media & General inquiries
Haute Capital Partners AG
+41 32 321 35 35 | info@haute.com